216571-44-7

Basic information

• Product Name: 9-(3,5-Di-O-benzoyl-2-deoxy-β-L-threo-pentofuranosyl)adenine
• Synonyms: 9-(3,5-Di-O-benzoyl-2-deoxy-β-L-threo-pentofuranosyl)adenine
• CAS NO: 216571-44-7
• Molecular Weight: 459.461
• Mol File: 216571-44-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 9-(3,5-Di-O-benzoyl-2-deoxy-β-L-threo-pentofuranosyl)adenine(CAS DataBase Reference)
• NIST Chemistry Reference: 9-(3,5-Di-O-benzoyl-2-deoxy-β-L-threo-pentofuranosyl)adenine(216571-44-7)
• EPA Substance Registry System: 9-(3,5-Di-O-benzoyl-2-deoxy-β-L-threo-pentofuranosyl)adenine(216571-44-7)

Safety Data

• Hazardous Substances Data: 216571-44-7(Hazardous Substances Data)

Upstream product

• 154463-68-0 9-(2-O-acetyl-3,5-di-O-benzoyl-β-L-xylofuranosyl)adenine 
• 1873-77-4 tris-(trimethylsilyl)silane 
• 34241-39-9 azobisisobutyronitrile 
• 216571-43-6 9-(3,5-di-O-benzoyl-β-L-xylofuranosyl)adenine 
• 201287-82-3 1,2-di-O-acetyl-3,5-di-O-benzoyl-β-L-xylofuranosyle 
• 66224-66-6 adenine 

Downstream Products

• 233681-07-7 C₄₄H₃₇N₅O₆ 
• 258529-64-5 (2S,3R,5S)-2-[(4-Methoxy-phenyl)-diphenyl-methoxymethyl]-5-(6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-purin-9-yl)-tetrahydro-furan-3-ol 
• 233681-09-9 (2S,3S,5S)-2-[(4-Methoxy-phenyl)-diphenyl-methoxymethyl]-5-(6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-purin-9-yl)-tetrahydro-furan-3-ol 
• 233681-08-8 (2S,3S,5S)-2-Hydroxymethyl-5-(6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-purin-9-yl)-tetrahydro-furan-3-ol 
• 14365-45-8 L-dA 

Relevant articles and documents

β-L-2'-deoxy-nucleosides for the treatment of hepatitis B

This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2''-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2''-deoxy-β-L-erythro-pentofuranonucleoside has the formula: STR1wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2''-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2''-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

Methods of treating hepatitis delta virus infection with beta-l-2'-deoxy-nucleosides

A method and composition for treating a host infected with hepatitis D comprising administering an effective hepatitis D treatment amount of a described 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof.

Unnatural β-L-enantiomers of nucleoside analogues as potent anti- hepatitis B virus agents

Several 2'- or 3'- substituted 2',3'-dideoxy-β-L-nucleosides bearing adenine as the base were stereospecifically synthesized and their antiviral properties examined. Two of them, namely 2'-azido- and 3'-azido-2',3'- dideoxy-β-L-adenosine (2'-N3